About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Kilitch Drugs (India) Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
10-Nov-2025
13-Nov-2025
Quarterly Results
07-Aug-2025
13-Aug-2025
Quarterly Results
30-Jun-2025
02-Jul-2025
Inter-alia transact the following; 1. To consider and approve the proposal for fund raising by way of issue of equity shares of face value of 10/-each (the ?Equity Shares?) through Rights Issue. 2. To consider and approve the deployment of the proceeds of the Right Issue. 3. To consider and approve the Draft Letter of Offer for fund raising by way of Right issue and to authorize for Application for in-principal approval for rights issue up to %50,00,00,000/- under Regulation 28(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. 4. To consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman.
13-May-2025
19-May-2025
Quarterly Results & Audited Results
03-Feb-2025
11-Feb-2025
Quarterly Results
04-Nov-2024
12-Nov-2024
Quarterly Results
01-Aug-2024
08-Aug-2024
Quarterly Results
21-May-2024
27-May-2024
Quarterly Results
31-Jan-2024
08-Feb-2024
Quarterly Results
01-Nov-2023
09-Nov-2023
Quarterly Results
04-Aug-2023
11-Aug-2023
Quarterly Results
19-Jul-2023
22-Jul-2023
Inter alia, to consider and approve conversion of warrants into the equity shares of the Company to the specified person only.
17-May-2023
29-May-2023
Audited Results
03-Feb-2023
14-Feb-2023
Quarterly Results
03-Nov-2022
14-Nov-2022
Quarterly Results
02-Aug-2022
10-Aug-2022
Quarterly Results
17-May-2022
26-May-2022
Audited Results
07-Feb-2022
14-Feb-2022
Quarterly Results
15-Dec-2021
20-Dec-2021
Preferential Issue of shares & Issue Of Warrants
02-Nov-2021
12-Nov-2021
Quarterly Results
Page
1
of
7
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.